基于PD-1/PD-L1抑制剂的非小细胞肺癌免疫治疗预测标志物的研究进展  

Advances in the study of predictive markers of immunotherapy for non-small cell lung cancer based on PD-1/PD-L1 inhibitors

作　　者：王佳慧 陈公琰[1] WANG Jiahui;CHEN Gongyan(Harbin Medical University Cancer Hospital,Heilongjiang Harbin 150000,China)

机构地区：[1]哈尔滨医科大学附属肿瘤医院呼吸内科,黑龙江哈尔滨150000

出　　处：《现代肿瘤医学》2021年第10期1822-1825,共4页Journal of Modern Oncology

摘　　要：肺癌的发病率及死亡率均居世界首位,其中非小细胞肺癌约占所有肺癌类型的85%,传统放化疗的有效率十分有限,靶向治疗的耐药问题广泛存在。随着对肿瘤免疫逃逸机制的不断深入研究,以PD-1/PD-L1抑制剂为首的免疫治疗有望为患者带来新的曙光。但相关临床研究提示,非选择人群只有约20%可从中获益,故筛选优势人群迫在眉睫。本文将对目前非小细胞肺癌PD-1/PD-L1抑制剂免疫治疗预测标志物的研究进展作一综述,旨在帮助临床更好的选择非小细胞肺癌免疫治疗优势人群,使患者最大程度获益。The morbidity and mortality of lung cancer are the highest in the world.Non-small cell lung cancer accounts for about 85% of all types of lung cancer.The effective rate of traditional radiotherapy and chemotherapy is very limited.Drug resistance in targeted therapy is widespread.With the further study of the mechanism of tumor immune escape,the immunotherapy led by PD-1/PD-L1 inhibitors is expected to bring a new dawn for patients.But related clinical studies suggest that only about 20% of the non-selected population can benefit from it,so it is urgent to screen the dominant population.This article will review the current research progress of PD-1/PD-L1 inhibitor immunotherapy predictive markers in non-small cell lung cancer,in order to help the clinical selection of non-small cell lung cancer immunotherapy superiority population,and to maximize the benefit of patients.

关 键 词：非小细胞肺癌 免疫治疗 PD-1/PD-L1抑制剂 标志物 

分 类 号：R734.2[医药卫生—肿瘤]